Consolidation in pharma, coupled to the trend for strategic partnerships, will lead to CRO mergers, with large companies getting bigger and small firms focusing on niche opportunities, according to a report.
Quotient Bioresearch has secured the supply of 14C labelled compounds for its customers ahead of its move to a new purpose built facility in Cardiff through an extension of its agreement with GE Healthcare (GEHC).
Patheon and JLL are to end the legal actions between them by entering into a litigation settlement which establishes a board of directors and limits JLL acquiring additional restricted voting shares before April 27 2012.
The recent wave of M&A will lead to manufacturing over-capacity at pharma companies but only a small number of these sites will be sold to CMOs, in part because of the facilities’ suboptimal locations, according to a report.
Icon is looking to expand its bioanalytical capacity in Asia, notably in China, and bolster its genomics, proteomics and cell-based assay capabilities, according to a VP who discussed diversification of the business.
MDS’ Central Labs has been rebranded as Clearstone Central Laboratories following its acquisition by Czura Thornton, which is looking to expand the business and that of Chiltern, a CRO also owned by the investment company, into new geographies, according...
The outsourcing “market is poised to return to healthier growth rates in 2010”, according to the president of MDS Pharma Services who also told Outsourcing-Pharma that CROs will play an increasingly important role in drug development.
With Lonza and JLL competing over Patheon Outsourcing-Pharma looks at what the CMO offers to a prospective buyer, analysing its global manufacturing capacity and backlog using interactive maps and graphs.
Bristol-Myers Squibb (B-MS) has outsourced the manufacture of some of its products to Sigma Pharmaceuticals, an Australia-based company that also bought a facility from the big pharma for A$60m ($51.7m).
By acquiring a stake in India-based RSIPL Evotec believes it can offer clients quicker drug development services, an important aspect of coping with attrition, because larger teams of chemists are available in emerging markets.
Facing “unparalleled” challenges MDS is seeking a buyer for its Pharma Services division, and claims to have begun discussions with two interested parties, to allow it to focus on its Nordion business.
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
Companies seeking research services in India and China will now be able to use a single contact following an alliance between GVK BIO and Excel, which the companies claim is the first to span the two nations.
Contract research organisation PPD has boosted its compound partnering programme with the purchase of dermatology specialist Magen BioSciences, and divested its presclinical research subsidiary Pedmont Research Centre.
The global economic downturn, impending blockbuster patent expiries and the wave of consolidation sweeping the pharmaceutical industry will drive demand for Patheon’s restructuring service according to CEO Wesley Wheeler.